Pharmacokinetic and pharmacodynamic properties of meropenem

Clinical Infectious Diseases

Volumn 47, Issue SUPPL.1, 2008, Pages

  Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL INFECTION; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; BODY FLUID; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; HOSPITAL INFECTION; HUMAN; KIDNEY DISEASE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SKIN STRUCTURE; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; BACTERIA; HUMANS; THIENAMYCINS;

EID: 51549120036     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/590064     Document Type: Review

References (57)

1. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
2. Drusano GL. Antimicrobial pharmacodynamics: critical interaction of "bug" and "drug." Nat Rev Microbiol 2004; 2:289-300.
3. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminogylcosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39:677-86.
4. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81.
5. Hatano K, Wakai Y, Watanabe Y, Mine Y. Simulation of human plasma levels of b-lactams in mice by multiple dosing and the relationship between the therapeutic efficacy and pharmacodynamic parameters. Chemotherapy 1994; 40:1-7.
6. Turnidge JD. The pharmacodynamics of b-lactams. Clin Infect Dis 1998; 27:10-22.
7. Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on b-lactam antibiotics; insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320-32.
8. MERREM I.V. (meropenem for injection) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2007.
9. Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother 1995; 36(Suppl A):43-56.
10. Condon RE, Walker AP, Hanna CB, Greenberg RN, Broom A, Pitkin D. Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Clin Infect Dis 1997; 24(Suppl 2):S181-3.
11. Bedikian A, Okamoto MP, Nakahiro RK, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother 1994; 38:151-4.
12. Gall S, Hemsell DL, McGregor JA, Martens MG, Pitkin D, Allen S. Tissue penetration of meropenem in patients undergoing gynecologic surgery. Clin Infect Dis 1997; 24(Suppl 2):S178-80.
13. Byl B, Jacobs F, Roucloux I, de Franquen P, Cappello M, Thys J-P. Penetration of meropenem in lung, bronchial mucosa, and pleural tissues. Antimicrob Agents Chemother 1999; 43:681-2.
14. Conte JE Jr, Golden JA, Kelley MG, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 2005; 26:449-56.
15. Newsom SWB, Palsingh J, Wells FC, Kelly HC. Penetration of meropenem into heart valve tissue. J Antimicrob Chemother 1995; 36(Suppl A):57-62.
16. Wise R, Logan M, Cooper M, Ashby JP, Andrews JM. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother 1990; 34:1515-7.
17. Maglio D, Teng R, Thyrum PT, Nightingale CH, Nicolau DP. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid. Antimicrob Agents Chemother 2003; 47:1771-3.
18. Leroy A, Fillastre JP, Borsa-Lebás F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 1992; 36:2794-8.
19. Leroy A, Fillastre JP, Etienne I, Borsa-Lebás F, Humbert G. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol 1992; 42:535-8.
20. Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 1993; 37:229-33.
21. Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 1992; 36:1532-7.
22. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venous hemofiltration. Antimicrob Agents Chemother 1998; 42:2417-20.
23. Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999; 65:50-7.
24. Krueger WA, Schroeder TH, Hutchison M, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998; 42:2421-4.
25. Kuti JL, Nicolau DP. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy 2005; 51:211-6.
26. Thyrum PT, Yeh C, Birmingham B, Lasseter K. Pharmacokinetics of meropenem in patients with liver disease. Clin Infect Dis 1997; 24(Suppl 2):S184-90.
27. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother 1992; 36:1437-40.
28. Blumer JL, Reed MD, Kearns GL, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother 1995; 39:1721-5.
29. Parker EM, Hutchison M, Blumer JL. The pharmacokinetics of meropenem in infants and children: a population analysis. J Antimicrob Chemother 1995; 36(Suppl A):63-71.
30. Du X, Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J Clin Pharmacol 2006; 46:69-75.
31. Craig WA, Ebert S, Watanabe Y. Differences in time above MIC (T > MIC) required for efficacy of beta-lactams in animal infection models [abstract 86]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993.
32. Ong CR, Tessier PR, Li C, Nightingale CH, Nicolau DP. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn Microbiol Infect Dis 2007; 57:153-61.
33. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004; 26:1187-98.
34. Maglio D, Banevicius MA, Sutherland C, Babalola C, Nightingale CH, Nicolau DP. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob Agents Chemother 2005; 49:276-80.
35. DeRyke CA, Banevicius MA, Fan HW, Nicolau DP. Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumonia in a neutropenic mouse thigh model. Antimicrob Agents Chemother 2007; 51:1481-6.
36. Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA Program. Diagn Microbiol Infect Dis 2005; 53:281-7.
37. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother 2004; 48:2464-70.
38. Masterton RG, Kuti JL, Turner PJ, Nicolau DP. The OPTAMA Programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 2005; 55:71-7.
39. Kiffer CRV, Mendes C, Kuti JL, Nicolau DP. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumonia, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Diagn Microbiol Infect Dis 2004; 49:109-16.
40. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamic evaluation of meropenem and cefotaxime for pediatric meningitis: a report from the OPTAMA Program. Paediatr Drugs 2006; 8:131-8.
41. Ong CT, Kuti JL, Nicolau DP, OPTAMA Program. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Surg Infect (Larchmt) 2005; 6:419-26.
42. Kotapati S, Kuti JL, Nicolau DP. Pharmacodynamic modeling of betalactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA Program. Surg Infect (Larchmt) 2005; 6:297-304.
43. Maglio D, Kuti JL, Nicolau DP. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA Program. Clin Ther 2005; 27:1032-42.
44. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the empiric treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 2005; 33:2222-7.
45. Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents 2006; 28:62-8.
46. Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39:32-8.
47. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51:1725-30.
48. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46:1171-8.
49. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43:1116-23.
50. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005; 49:461-3.
51. Jaruratanasirikul S, Sriwiriyajan S. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J Antimicrob Chemother 2003; 52:518-21.
52. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005; 49:1337-9.
53. Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005; 49:1881-9.
54. Thalhammer F, Traunmüller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999; 43:523-7.
55. Moczygemba LR, Frei CR, Burgess DS. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin Ther 2004; 26:1800-7.
56. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66:1-14.
57. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:4920-7.